KRYS — Krystal Biotech Share Price
0.000.00%
Last trade - 00:00- $4.35bn
- $3.67bn
- $290.52m
- 87
- 33
- 37
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.43 | ||
| PEG Ratio (f) | 0.74 | ||
| EPS Growth (f) | 43.51% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.18 | ||
| Price to Tang. Book | 4.18 | ||
| Price to Free Cashflow | 23.45 | ||
| Price to Sales | 12.11 | ||
| EV to EBITDA | 25.23 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.25% | ||
| Return on Equity | 15.61% | ||
| Operating Margin | 38.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 50.7 | 290.51 | 382.6 | 565.65 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +18.82 | +55.99 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Directors
- Krish Krishnan CHM (56)
- Suma Krishnan FDR (56)
- Bhushan Hardas CEX
- Kathryn Romano CAO (40)
- Jing Marantz OTH (57)
- Andy Orth OTH
- Daniel Janney LED (55)
- Everett Sutherland DRC (51)
- Julian Gangolli IND (63)
- Kirti Ganorkar IND (54)
- Christopher Mason IND (63)
- Dino Rossi IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- March 31st, 2017
- Public Since
- September 20th, 2017
- No. of Shareholders
- 2
- No. of Employees
- 275
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 28,942,981
- Address
- 2100 Wharton St Ste 701, PITTSBURGH, 15203-1973
- Web
- https://www.krystalbio.com/
- Phone
- +1 4125865830
- Contact
- Meg Dodge
- Auditors
- KPMG LLP
Upcoming Events for KRYS
Similar to KRYS
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Krystal Biotech share price?
As of Today at 21:38 UTC, shares in Krystal Biotech are trading at $150.27. This share price information is delayed by 15 minutes.
How has the Krystal Biotech share price performed this year?
Shares in Krystal Biotech last closed at $150.27 and the price had moved by -22.53% over the past 365 days. In terms of relative price strength the Krystal Biotech share price has underperformed the S&P500 Index by -33.29% over the past year.
What are the analyst and broker recommendations for Krystal Biotech?
The overall consensus recommendation for Krystal Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Krystal Biotech dividend yield?
Krystal Biotech does not currently pay a dividend.
Does Krystal Biotech pay a dividend?
Krystal Biotech does not currently pay a dividend.
When does Krystal Biotech next pay dividends?
Krystal Biotech does not currently pay a dividend.
How do I buy Krystal Biotech shares?
To buy shares in Krystal Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Krystal Biotech?
As of the previous close price of $150.27, shares in Krystal Biotech had a market capitalisation of $4.35bn.
Where are Krystal Biotech shares listed?
Here are the trading details for Krystal Biotech:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KRYS
What kind of share is Krystal Biotech?
Based on an overall assessment of its quality, value and momentum Krystal Biotech is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Krystal Biotech share price forecast for 2025?
The analyst consensus target price for shares in Krystal Biotech is $206.09. That is 37.15% above the last closing price of $150.27.
Analysts covering Krystal Biotech currently have a consensus Earnings Per Share (EPS) forecast of $4.96 for the next financial year.
Find out moreWhat is the trend in the Krystal Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Krystal Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -6.81%.
As of the last closing price of $150.27, shares in Krystal Biotech were trading -6.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Krystal Biotech PE Ratio?
The Krystal Biotech PE ratio based on its reported earnings over the past 12 months is 22.43. The shares last closed at $150.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Krystal Biotech?
Krystal Biotech's management team is headed by:
- Krish Krishnan - CHM
- Suma Krishnan - FDR
- Bhushan Hardas - CEX
- Kathryn Romano - CAO
- Jing Marantz - OTH
- Andy Orth - OTH
- Daniel Janney - LED
- Everett Sutherland - DRC
- Julian Gangolli - IND
- Kirti Ganorkar - IND
- Christopher Mason - IND
- Dino Rossi - IND